Please assess the completion status of the following clinical trial:

Trial Title: A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male, age ≥ 18 years.~* Histologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version 1.1.~* Patients must have a history of brain metastases that are non-progressing.~* For triple-negative breast cancer, a minimum of 1 prior cytotoxic chemotherapy regimen must have been administered for the indication of metastatic disease.Depending on receptor status, 1 or 2 prior cytotoxic regimens are required prior to enrollment in this trial; hormonal and/or human epidermal growth factor receptor 2 (HER2) -targeted agents may be required.~* Have had prior therapy (administered in the neoadjuvant, adjuvant, and/or metastatic setting) with an anthracycline, a taxane, and capecitabine (prior anthracycline can be omitted if not medically appropriate or contraindicated for the patient).~* Last dose of anticancer therapy must have been administered within 6 months of the date of randomization into this study.~* All anticancer- and radiation therapy-related toxicities must be completely resolved or downgraded to Grade 1 or less (neuropathy may be Grade 2 or less).~* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Demonstrate adequate organ function obtained within 14 days prior to randomization and analyzed by the central laboratory.~* Women of childbearing potential (WCBP) must agree to use highly effective methods of birth control throughout the duration of the study until 6 months following the last dose of study drug.~* Males with female partners of child-bearing potential must agree to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/suppository) throughout the duration of the study until 6 months following the last dose of study drug; in addition to their female partner using either an intrauterine device or hormonal contraception and continuing until 6 months following the last dose of study drug. Male patients should not donate sperm until 6 months following the last dose of study drug.~Exclusion Criteria:~* Last dose of anticancer therapy (including HER2-targeted therapy) within 14 days prior to randomization.~* High-dose chemotherapy followed by stem cell transplantation (autologous or allogeneic).~* Major surgery within 28 days prior to randomization.~* Concomitant use of any anticancer therapy or use of any investigational agent(s).~* Received prior treatment for cancer with a camptothecin-derived agent.~* Lesions on imaging, by cerebrospinal fluid or with neurological findings that are consistent with leptomeningeal disease or meningeal carcinomatosis.~* Chronic or acute GI disorders resulting in diarrhea of any severity grade.~* Patients who are pregnant or lactating, plan to get pregnant, or have a positive serum pregnancy test prior to randomization.~* Enzyme-inducing anti-epileptic drugs (EIAEDs) within 14 days of randomization.~* Hepatitis B or C, tuberculosis, or HIV.~* Cirrhosis.~* Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization.~* Daily use of oxygen supplementation.~* Significant known cardiovascular impairment.~* Prior treatment with NKTR-102.~* Psychiatric illness, social situation, or geographical situation that preclude informed consent or limit compliance.~* Known intolerance or hypersensitivity to any of the products used in this study or their excipients.~* For patients selecting vinorelbine or gemcitabine as the TPC agent, patients may not receive yellow fever vaccine in the 28 days prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NKTR-102 (Type: EXPERIMENTAL): In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
- Treatment of Physician's Choice (TPC) (Type: ACTIVE_COMPARATOR): In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).